Xanomeline-trospium: defining its place among the current antipsychotic landscape.

A Phase 3 ARISE trial conducted by Bristol Myers Squibb (BMS) evaluated xanomeline/trospium, and even though xanomeline/trospium demonstrated a 2.0 point greater reduction in PANSS total score compared to placebo; the difference did not reach statistical significance ( ARISE clinical trial (KAR-012), 2025).

also in 111,027 other papers

In patients with Alzheimer’s disease, xanomeline not only showed a positive trend towards cognitive improvement, but also led to an unexpected reduction in behavioural disturbances, including hallucinations, vocal outbursts, and agitation (Bodick et al., 1997 ).

also in 11,005 other papers